(Morning News) The World Health Organization stated that the crown disease vaccine that has been urgently used by the WHO is still valid for the Omikon variants, but the existing vaccine may still be updated to continue to provide people with providing people withSuccessive protection to cope with the current and future variant of coronary virus.
Xinhua News Agency reported that the WHO issued a statement on Tuesday (January 11) that experts from the WHO Corruption Vaccine Technical Consultation Group are currently analyzing evidence related to the need to care about variants, andIt may be modified according to this advice on the component of the coronary vaccine.
The WHO lists variable strains as "Variant OFCONCERN" or "Variant of Interest" based on the transmission of coronary virus, pathogenicity, pathogenicity, etc., Omikon and Delta are both concerned about variants.
The WHO Coronatte Vaccine Component Technology Consulting Group was established in September last year and consists of 18 different discipline experts.The expert group issued a temporary statement on the 11th that the crown disease vaccine that has been urgently used by the WHO has obtained the urgent use of certified certification for Omikon and others.EssenceBut at the same time, experts also emphasized that in the future, the development of vaccines that can better prevent coronary virus infection and spread.
In addition, with the mutation of the coronary virus, the ingredients of the existing vaccine may need to be updated to ensure that in the face of other may be caused by other possible variants that may be concerned about the future.When infection and disease, the protection level of WHO proposal is continued.
Specifically, the updated vaccine's components need to be similar to the transmitted variety strains on genes and antigens."Immune response to" reduce the demand for continuous additives. "
WHO also proposes some update solution options, including the development of unit -price vaccines for major popular variety strains, multi -price vaccine or development continuity for multi -price vaccines that must be concerned about variety of strain antigen from various types of antigen.For long -term vaccines that can still be effective for different variants.
For Omikon, which is currently popular in many countries, the expert group has called on global extensive promotion of complete vaccination and additional additional vaccination plans. I hope that this will help reduce the emergence of new variants.And reduce its harm.
